2013 seminar schedule

ABOUT AFRRI | A–Z INDEX | CONTACT US

EMERGENCY RESPONSE

AFRRI 50th Anniversary Symposia

Biodosimetry Tools

Emergency Response Resources
Advisory team
Other resources

Managing Radiation Casualties
POLICIES
  Depleted uranium
  Potassium iodide
  Prussian blue
PUBLICATIONS
  Radiation patient treatment
  Managing radiological casualties
  Response to nuclear detonation
      • 1st Edition (Jan 2009)
      • 2nd Edition (Jun 2010)
  NCRP recommendations
  Consequences of nuclear warfare

Medical Effects of Ionizing Radiation
  In-person course
  Online course
  Schedule, fees, registration
  Course resources

Product Quick List
  Exposure assessment tools
  Forms
  Guidance

Publications
  Books/book chapters
  Contract reports/films
  Journal articles/supplements
  Reports/report chapters
  Scientific reports
  Special publications
  Technical reports

Register AFRRI Products

Research Programs
  Biological dosimetry
  Radiation combined injury
  Internal contamination/toxic metals
  Radiation countermeasures

2013 AFRRI Seminars

USU Dept. of Radiation Biology

You are here: HOME > Seminars > 2013 seminar schedule
2013 AFRRI Seminars
Jump to: 2013 \| 2012 \| 2011 \| 2010 \| 2009 \| 2008 \| 2007 \| 2006 \| 2005 \| 2004 \| 2003
Venue
Time: 10:30 to 11:30 a.m. (unless otherwise noted) each Wednesday Place: AFRRI Conference Room, unless otherwise indicated.
Directions to AFRRI \| Base map \| Security, base access, parking
Seminars are presented by AFRRI researchers and other members of the scientific community. While some seminars are open to the public, others are limited to specific audiences. Any exceptions to time, place, and admittance are noted with each item. We do not record or distribute information presented in our Seminar Program. However, where available, references to related information are provided with the seminar title.
2013 seminar schedule
Wednesday, May 8: Murali K. Cherukari, PhD, Research Biophysicist, Principal Investigator, Center for Cancer Research Chief, Biophysical Spectroscopy Section Radiation Biology Branch, National Cancer Institute National Institutes of Health, Bethesda MD: Magnetic resonance imaging of tumor physiology and metabolic profile in vivo. Related information: Echo-based Single Point Imaging (ESPI): A novel pulsed EPR imaging modality for high spatial resolution and quantitative oximetry. J Magn Reson. 218:105–114, 2012. Reporting of quantitative oxygen mapping in EPR imaging. J Magn Reson. 214: 244–251, 2012. Electron paramagnetic resonance imaging of tumor pO₂. Radiat Res. 177: 376–386, 2012. Wednesday, May 1: Mansoor M. Ahmed, PhD, Program Director, Radiotherapy Development Branch (RDB), Radiation Research Program, Division of Cancer Treatment and Diagnosis National Cancer Institute, National Institutes of Health, Rockville, MD: Signal transduction pathways and radiation response. Related information: A realistic utilization of nanotechnology in molecular imaging and targeted radiotherapy of solid tumors (Review: Selected for Cover). Radiat Res. 177:483–495, 2012. Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells. Mol Cancer Ther. 10:292–302, 2011. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo. Int J Radiat Oncol Biol Phys. 79:549–558, 2011. Wednesday, April 24: Lynnette Cary, PhD, Staff Scientist (Henry M. Jackson Foundation), Radiation Countermeasures Program, AFRRI: Identification of effective countermeasures against mixed neutron/gamma radiation: Progress and challenges. Related information: Ciprofloxacin modulates cytokine/chemokine profile in serum, improves bone marrow repopulation, and limits apoptosis and autophagy in ileum after whole body ionizing irradiation combined with skin-wound trauma. PLoS ONE 8:e58389, 2013. Efficacy of radiation countermeasures depends on radiation quality. Radiat Res. 177:663–675, 2012. Gamma-tocotrienol, a radiation prophylaxis agent, induces high levels of granulocyte colony-stimulating factor. Int Immunopharmacol. 14:495–503, 2012. Wednesday, April 3: Joel Lowy, PhD, Principal Investigator, AFRRI: Update on understanding macrophage responses to ionizing radiation and PAMPS. Wednesday, March 27: Gregory L. King, PhD, Research Physiologist, Radiation Countermeasures Program, AFRRI: Radiation dose rate effects on selected biomarkers of radiation injury: A modest proposal. Related information: 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation. Aviat Space Environ Med. 70:485–492, 1999. Plasticity of autonomic control of emesis in irradiated ferrets. Am J Physiol. 265:R1092–R1099, 1993. Characterization of radiation-induced emesis in the ferret. Radiat Res. 114:599–612, 1988. Wednesday, March 20: John F. Kalinich, PhD, Program Advisor, Internal Contamination and Metal Toxicity Program, AFRRI: Embedded metal fragments: Short-term medical problem or long-term health risk. Related information: Radiation Metabolomics. 5. Identification of urinary biomarkers of ionizing radiation exposure in non-human primates by mass spectrometry-based metabolomics. Radiat Res. 178:328–340, 2012. The use of established skeletal muscle cell lines to assess potential toxicity from embedded metal fragments. Toxicol In Vitro 23:356–359, 2009. Protocol for the assessment of potential health effects from embedded metal fragments. Mil Med. 174:265–269, 2009. Wednesday, March 13: Mark H. Whitnall, PhD, Program Advisor, Radiation Countermeasures Program, AFRRI: How does science work? Related information: Efficacy of radiation countermeasures depends on radiation quality. Radiat Res. 177:663–675, 2012. 5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis. J Radiat Res. 53:840–853, 2012. Hematological changes as prognostic indicators of survival: Similarities between Gottingen minipigs, humans, and other large animal models. PLoS ONE 6:e25210, 2011. Wednesday, February 27: Natalia I. Ossetrova, PhD, Research Biologist, Biological Dosimetry Program, AFRRI: ARS severity scoring system and radiation dose assessment in mouse total-body irradiation model. Related information: Murine partial-body radiation exposure model for biodosimetry studies—Preliminary report. Radiat Meas. 46: 898–902, 2011. Multiple parameter radiation injury assessment using a nonhuman primate radiation model—Biodosimetry applications. Health Phys. 98:153–159, 2010. Combined approach of hematological biomarkers and plasma protein SAA for improvement of radiation dose assessment in triage biodosimetry applications. Health Phys. 98:204–208, 2010. Wednesday, February 20: William F Blakely, PhD, Program Advisor, Biological Dosimetry, AFRRI: Further updates on translational biodosimetry research activities. Related information: Optimization of calyculin A-induced premature chromosome condensation assay for chromosome aberration studies. Cytometry A. 79:1016–1022, 2011. Q(γ-H2AX), an analysis method for partial-body radiation exposure using γ-H2AX in nonhuman primate lymphocytes. Radiat Meas. 46:877–881, 2011. The use of gamma-H2AX as a biodosimeter for total-body radiation exposure in non-human primates. PLoS One 5:e15544, 2010. Friday, February 15: Michael R. Landauer, PhD, Research Toxicologist, AFRRI: Radiation protection by genistein: Past, present, and future. Related information: Captopril modulates hypoxia-inducible factors and erythropoietin responses in a murine model of total-body irradiation. Expt Hematol. 39:293–304, 2011. Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total-body irradiation. Expt Hematol. 38:270–281, 2010. History and development of radiation-protective agents. Int J Radiat Biol. 85:539–573, 2009. Wednesday, February 6: R. Dustan Sarazan, DVM, PhD, Vice President and Chief Scientific Officer, Data Sciences International, St. Paul, MN: Physiologic monitoring in unrestrained animals: Application of telemetry to risk assessment and countermeasure development following exposure to ionizing radiation in animal models. Related information: Left ventricular pressure, contractility and dP/dt(max) in nonclinical drug safety assessment studies. J. Pharmacol Toxicol Methods 66:71–8. doi:10.1016/j.vascn.2012.05.009, 2012. Cardiovascular function in nonclinical drug safety assessment: Current issues and opportunities. Int J Toxicol. 30:272-86. doi: 10.1177/1091581811398963, 2011. Standing on the shoulders of giants: Dean Franklin and his remarkable contributions to physiological measurements in animals. Adv Physiol Educ. 33:144–56, 2009. Wednesday, January 30: Juliann G. Kiang, PhD, Program Advisor, Radiation Injury Combined with Other Trauma Program, AFRRI: Radiation combined injury: Biological effects and countermeasures. Related information: Wound trauma alters ionizing radiation dose assessment. Cell Biosci. 2:20, 2012 (doi: 10.1186/2045-3701-2-20). 17-DMAG diminishes hemorrhage-induced small intestine injury by elevating Bcl-2 protein and inhibiting iNOS pathway, TNF-α increase, and caspase-3 activation. Cell Biosci. 1:21, 2011 (doi: 10.1186/2045-3701-1-21). Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat shock protein 90 kDa after ionizing radiation. Radiat Res. 176:333–345, 2011. Wednesday, January 23: Vijay K. Singh, PhD, Associate Professor, Acting Chair, Radiation Biology Department, F. Edward Hébert School of Medicine, Radiation Countermeasure Program, AFRRI, USUHS: Myeloid progenitors mitigate radiation injury and improve intestinal integrity after whole-body irradiation. Related information: Myeloid progenitors: A radiation countermeasure that is effective when initiated days after irradiation. Radiat Res. 177:781–791, 2012. CBLB613: A TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. Radiat Res. 177:628–642, 2012. Identification of G-CSF and IL-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther. 343:497–508, 2012. Friday, January 11: Jerry K. Davis, DVM, PhD, DACLAM, Consultant, Office of Counter-Terrorism & Emergency Coordination DDHS/FDA/CDER/OCTEC, Silver Spring, MD: Animal Model Qualification Program: An overview. Related information: Mycoplasma pulmonis and lymphoma. Environ Mol Mutagen. 50: 1–3, 2009. Mycoplasma pulmonis and lymphoma bioassay in rats. Vet Pathol. 45:952–959, 2009. Comment on "Barrier facilities for transgenic rodents in academic centers—a two-edged sword." Comp Med. 53:116–118, 2003. Friday, January 4: Mark G. Kortepeter, MD, MPH, Director, Infectious Disease Clinical Research Program, Associate Professor of Preventive Medicine, F. Edward Hébert School of Medicine, USUHS: Ebola virus: Using telemetry to gain new insights into a deadly disease. Related information: Sulfur mustard: A liquid not a gas [Letter]. Clin Infect Dis. 54:885–886, 2012. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis. 204:S1000–1010, 2011. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 204:S810–816, 2011.
TOP OF PAGE